Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
2000 2
2006 1
2007 1
2008 1
2013 1
2014 1
2015 1
2017 2
2018 2
2019 2
2020 6
2021 1
2022 2
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial.
Nabbout R, Mistry A, Zuberi S, Villeneuve N, Gil-Nagel A, Sanchez-Carpintero R, Stephani U, Laux L, Wirrell E, Knupp K, Chiron C, Farfel G, Galer BS, Morrison G, Lock M, Agarwal A, Auvin S; FAiRE, DS Study Group. Nabbout R, et al. JAMA Neurol. 2020 Mar 1;77(3):300-308. doi: 10.1001/jamaneurol.2019.4113. JAMA Neurol. 2020. PMID: 31790543 Free PMC article. Clinical Trial.
IMPORTANCE: Fenfluramine treatment may reduce monthly convulsive seizure frequency in patients with Dravet syndrome who have poor seizure control with their current stiripentol-containing antiepileptic drug regimens. OBJECTIVE: To determine whether fenfluramine reduced mon …
IMPORTANCE: Fenfluramine treatment may reduce monthly convulsive seizure frequency in patients with Dravet syndrome who have poor seizure co …
Stiripentol: A Novel Antiseizure Medication for the Management of Dravet Syndrome.
Buck ML, Goodkin HP. Buck ML, et al. Ann Pharmacother. 2019 Nov;53(11):1136-1144. doi: 10.1177/1060028019856008. Epub 2019 Jun 6. Ann Pharmacother. 2019. PMID: 31167540 Clinical Trial.
Objective: To describe the pharmacology, efficacy, and safety of stiripentol in the treatment of refractory seizures in patients with Dravet syndrome. ...Reductions in seizure duration and episodes of status epilepticus have also been documented. Common adverse effects inc …
Objective: To describe the pharmacology, efficacy, and safety of stiripentol in the treatment of refractory seizures in patients with …
Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis.
Guerrini R, Chiron C, Vandame D, Linley W, Toward T. Guerrini R, et al. Epilepsia Open. 2024 Apr;9(2):689-703. doi: 10.1002/epi4.12923. Epub 2024 Mar 1. Epilepsia Open. 2024. PMID: 38427284 Free PMC article.
OBJECTIVES: Stiripentol, fenfluramine, and cannabidiol are licensed add-on therapies to treat seizures in Dravet Syndrome (DS). ...Stiripentol was the best drug for stopping seizures completely based on the available clinical trial data. ...
OBJECTIVES: Stiripentol, fenfluramine, and cannabidiol are licensed add-on therapies to treat seizures in Dravet Syndrome (DS). ... …
Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome.
Devinsky O, Patel AD, Thiele EA, Wong MH, Appleton R, Harden CL, Greenwood S, Morrison G, Sommerville K; GWPCARE1 Part A Study Group. Devinsky O, et al. Neurology. 2018 Apr 3;90(14):e1204-e1211. doi: 10.1212/WNL.0000000000005254. Epub 2018 Mar 14. Neurology. 2018. PMID: 29540584 Free PMC article. Clinical Trial.
Multiple pharmacokinetic blood samples were taken on the first day of dosing and at end of treatment for measurement of CBD, its metabolites 6-OH-CBD, 7-OH-CBD, and 7-COOH-CBD, and antiepileptic drugs (AEDs; clobazam and metabolite N-desmethylclobazam [N-CLB], valproate, levetira …
Multiple pharmacokinetic blood samples were taken on the first day of dosing and at end of treatment for measurement of CBD, its metabolites …
New anticonvulsant drugs. Focus on flunarizine, fosphenytoin, midazolam and stiripentol.
Bebin M, Bleck TP. Bebin M, et al. Drugs. 1994 Aug;48(2):153-71. doi: 10.2165/00003495-199448020-00003. Drugs. 1994. PMID: 7527321 Review.
There are significant metabolic drug interactions between stiripentol and phenytoin, carbamazepine and phenobarbital (phenobarbitone). Stiripentol has been studied in patients with partial seizures, refractory epilepsy and refractory absence seizures with some effic …
There are significant metabolic drug interactions between stiripentol and phenytoin, carbamazepine and phenobarbital (phenobarbitone) …
Reassessment of stiripentol pharmacokinetics in healthy adult volunteers.
Peigné S, Rey E, Le Guern ME, Dulac O, Chiron C, Pons G, Jullien V. Peigné S, et al. Epilepsy Res. 2014 Jul;108(5):909-16. doi: 10.1016/j.eplepsyres.2014.03.009. Epub 2014 Mar 26. Epilepsy Res. 2014. PMID: 24725808 Clinical Trial.
Because children who have been receiving stiripentol for the treatment of Dravet syndrome for more than 10 years are now becoming young adults, it is important to accurately characterize stiripentol pharmacokinetics in this age range. ...Pharmacokinetics of stiri …
Because children who have been receiving stiripentol for the treatment of Dravet syndrome for more than 10 years are now becoming you …
Stiripentol in childhood partial epilepsy: randomized placebo-controlled trial with enrichment and withdrawal design.
Chiron C, Tonnelier S, Rey E, Brunet ML, Tran A, d'Athis P, Vincent J, Dulac O, Pons G. Chiron C, et al. J Child Neurol. 2006 Jun;21(6):496-502. doi: 10.1177/08830738060210062101. J Child Neurol. 2006. PMID: 16948934 Clinical Trial.
To limit the number of patients included, we used an enrichment and withdrawal design. Among the 67 children entered in a 4-month open add-on stiripentol study following a 1-month single-blind placebo baseline, the 32 responders were randomized for 2 months either to conti …
To limit the number of patients included, we used an enrichment and withdrawal design. Among the 67 children entered in a 4-month open add-o …
Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group.
Chiron C, Marchand MC, Tran A, Rey E, d'Athis P, Vincent J, Dulac O, Pons G. Chiron C, et al. Lancet. 2000 Nov 11;356(9242):1638-42. doi: 10.1016/s0140-6736(00)03157-3. Lancet. 2000. PMID: 11089822 Clinical Trial.
METHODS: After a baseline period of 1 month, placebo (n=20) or stiripentol (n=21) was added to valproate and clobazam during a double-blind period of 2 months. ...FINDINGS: 15 (71%) patients were responders on stiripentol (including nine free of clonic or tonic-clon …
METHODS: After a baseline period of 1 month, placebo (n=20) or stiripentol (n=21) was added to valproate and clobazam during a double …
Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Lattanzi S, Trinka E, Russo E, Del Giovane C, Matricardi S, Meletti S, Striano P, Damavandi PT, Silvestrini M, Brigo F. Lattanzi S, et al. Drugs. 2023 Oct;83(15):1409-1424. doi: 10.1007/s40265-023-01936-y. Epub 2023 Sep 11. Drugs. 2023. PMID: 37695433 Free PMC article.
RESULTS: Eight placebo-controlled trials were included, and the active add-on treatments were stiripentol (n = 2), pharmaceutical-grade cannabidiol (n = 3), fenfluramine hydrochloride (n = 2), and soticlestat (n = 1). ...Stiripentol had a higher risk of AE occurrenc …
RESULTS: Eight placebo-controlled trials were included, and the active add-on treatments were stiripentol (n = 2), pharmaceutical-gra …
A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug-Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy.
Ben-Menachem E, Gunning B, Arenas Cabrera CM, VanLandingham K, Crockett J, Critchley D, Wray L, Tayo B, Morrison G, Toledo M. Ben-Menachem E, et al. CNS Drugs. 2020 Jun;34(6):661-672. doi: 10.1007/s40263-020-00726-4. CNS Drugs. 2020. PMID: 32350749 Free PMC article. Clinical Trial.
RESULTS: In total, 35 patients were recruited to the stiripentol arm (n = 14) or the valproate arm (n = 21). Both the safety and the pharmacokinetic populations of the stiripentol arm comprised 14 patients (2 placebo; 12 cannabidiol). ...Two patients discontinued ca …
RESULTS: In total, 35 patients were recruited to the stiripentol arm (n = 14) or the valproate arm (n = 21). Both the safety and the …
24 results

Searches related to "stiripentol"